Three of the recalls, which BD announced on Aug. 4, 2020, have been designated as Class I recalls by the U.S. Food and Drug Administration (FDA), which means that FDA has determined that there is a reasonable probability that the use of the product will cause serious adverse health consequences or d

Summary of opinion: Yervoy,ipilimumab, 17/09/2020, Positive

Summary of opinion: Obiltoxaximab SFL,obiltoxaximab, 17/09/2020, Positive